Building a Clinical Operations Leadership Bench at a Small Biotech

A twelve-person biotech running its first trial has no leadership bench. It has a VP of Clinical Development, possibly a clinical operations director, and a CRO. That structure gets a Phase 1 study executed. It does not survive the transition to a multi-study program.

The failure point is predictable. When the second and third studies start, the same two people are asked to absorb double the oversight load. Decision quality drops before headcount problems become visible on a spreadsheet. Vendor issues get noticed later. Protocol deviations accumulate. Nobody is doing anything wrong; there is simply no capacity left for judgment.

Building a bench early does not mean hiring ahead of funding. It means distributing decision rights before capacity runs out. Three moves make the difference.

First, document the decisions that actually require executive input and the ones that do not. Most small sponsors never make this distinction, which means everything routes upward by default. A written decision-rights matrix covering protocol deviations, vendor escalations, budget variances, and safety communications frees senior leaders from adjudicating routine items.

Second, develop the people already in seat rather than assuming the next hire solves it. A clinical trial manager who has run one study can be deliberately stretched into oversight responsibility for a second, with structured support. That costs less than a director-level hire and produces a leader who understands the company's specific programs.

Third, treat the CRO relationship as a development opportunity rather than a black box. Sponsor staff who sit in on CRO functional meetings, review vendor deliverables critically, and participate in governance sessions learn faster than staff who receive summaries.

Small sponsors often resist this because it feels like overhead during a period when every dollar belongs to the science. The counter-argument is straightforward. A leadership gap discovered during a pivotal trial costs far more than the modest investment required to close it during Phase 1. Clinical leadership capacity is infrastructure, and infrastructure is cheaper to build before it is urgently needed.